EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

J‐AVENUE: A retrospective, real‐world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first‐line maintenance therapy in Japan

Eiji Kikuchi iD, Nozomi Hayakawa, Masashi Nakayama, Masahiro Uno, Hiroomi Nakatsu, Chiyoe Kitagawa, Hideaki Miyake, Takeshi Yamada, Kazutoshi Fujita, Hideaki Shimoyama, Kiyoaki Nishihara, Mizuki Kobayashi iD und 8 weitere

International Journal of Urology · 2024

DOI: 10.1111/iju.15473 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2024. Verfasst von Eiji Kikuchi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Maintenance Chemotherapy. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The JAVELIN Bladder 100 phase 3 trial showed that avelumab first‐line maintenance + best supportive care significantly prolonged overall survival and progression‐free survival versus best supportive care alone in patients with advanced urothelial carcinoma who were progression‐free following first‐line platinum‐based chemotherapy. We report findings from J‐AVENUE (NCT05431777), a real‐world study of avelumab first‐line maintenance therapy in Japan.

Methods

Medical charts of patients with advanced urothelial carcinoma without disease progression following first‐line platinum‐based chemotherapy, who received avelumab maintenance between February and November 2021, were reviewed. Patients were followed until June 2022. The primary endpoint was patient characteristics; secondary endpoints included time to treatment failure and progression‐free survival.

Results

In 79 patients analyzed, median age was 72 years (range, 44–86). Primary tumor site was upper tract in 45.6% and bladder in 54.4%. The most common first‐line chemotherapy regimen was cisplatin + gemcitabine (63.3%). Median number of chemotherapy cycles received was four. Best response to chemotherapy was complete response in 10.1%, partial response in 58.2%, and stable disease in 31.6%. Median treatment‐free interval before avelumab was 4.9 weeks. With avelumab first‐line maintenance therapy, the disease control rate was 58.2%, median time to treatment failure was 4.6 months (95% CI, 3.3–6.4), and median progression‐free survival was 6.1 months (95% CI, 3.6–9.7).

Conclusions

Findings from J‐AVENUE show the effectiveness of avelumab first‐line maintenance in patients with advanced urothelial carcinoma in Japan in clinical practice, with similar progression‐free survival to JAVELIN Bladder 100 and previous real‐world studies, supporting its use as a standard of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Transitional CellMaintenance ChemotherapyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsJapanProgression-Free SurvivalRetrospective StudiesTreatment OutcomeUrinary Bladder NeoplasmsUrologic Neoplasms

Stichwörter der Autor:innen

avelumabimmunotherapyreal world clinical trialstreatment outcomeurothelial carcinoma

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalavelumab

Autor:innen und Institutionen

  • Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan.
  • Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Urology, Ogaki Municipal Hospital, Gifu, Japan.
  • Department of Urology, Asahi General Hospital, Chiba, Japan.
  • Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, Aichi, Japan.
  • Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan.

ORCID-Profile: Eiji Kikuchi, Mizuki Kobayashi, Kiyohide Fujimoto, Takeshi Sano, Takashi Kobayashi

Förderung

  • Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA
  • Pfizer

Zitieren

APA

Kikuchi, E., Hayakawa, N., Nakayama, M., Uno, M., Nakatsu, H., Kitagawa, C., Miyake, H., Yamada, T., Fujita, K., Shimoyama, H., Nishihara, K., Kobayashi, M., Nakamura, M., Fujimoto, K., Sano, T., Nishiyama, N., Ito, T., Kajita, M., Kobayashi, T., & Kitamura, H. (2024). J‐AVENUE: A retrospective, real‐world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first‐line maintenance therapy in Japan. International Journal of Urology. https://doi.org/10.1111/iju.15473

Vancouver

Kikuchi E, Hayakawa N, Nakayama M, Uno M, Nakatsu H, Kitagawa C, et al. J‐AVENUE: A retrospective, real‐world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first‐line maintenance therapy in Japan. International Journal of Urology. 2024. doi:10.1111/iju.15473

BibTeX
@article{Kikuchi2024,
  author = {Kikuchi, Eiji and Hayakawa, Nozomi and Nakayama, Masashi and Uno, Masahiro and Nakatsu, Hiroomi and Kitagawa, Chiyoe and Miyake, Hideaki and Yamada, Takeshi and Fujita, Kazutoshi and Shimoyama, Hideaki and Nishihara, Kiyoaki and Kobayashi, Mizuki and Nakamura, Motonobu and Fujimoto, Kiyohide and Sano, Takeshi and Nishiyama, Naotaka and Ito, Takayuki and Kajita, Masahiro and Kobayashi, Takashi and Kitamura, Hiroshi},
  title = {J‐AVENUE: A retrospective, real‐world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first‐line maintenance therapy in Japan},
  journal = {International Journal of Urology},
  year = {2024},
  doi = {10.1111/iju.15473}
}
Kostenlos starten →